Technetium Tc 99m Demobesin-4 for Imaging Procedures in Patients With Prostate Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed prostate cancer meeting 1 of the following criteria:
• * Disease confined to the prostate that is to be treated with radical prostatectomy after imaging
• * Locally advanced disease that is to be treated with radiotherapy
• * Patients must agree to undergo surgical pelvic lymph node staging to assist with determination of radiation fields
• * Metastatic disease at initial diagnosis or recurrent or progressive disease
• * Patients receive standard of care
• PATIENT CHARACTERISTICS:
• WHO performance status 0-2
• Neutrophils ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hemoglobin ≥ 9.0 g/dL
• Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)
• Serum creatinine ≤ 1.5 times ULN
• Must be registered with the Cancer Research UK Drug Development Office
• Capable of cooperating with imaging procedure and follow-up
• Fertile patients must use effective contraception during and for 6 months after completion of study therapy
• Not at high medical risk because of non-malignant systemic disease, including active uncontrolled infection
• No history of recent significant cardiac arrhythmia
• No prior NYHA class III-IV cardiac disease or concurrent congestive heart failure
• No other condition that, in the Investigator's opinion, would not make the patient a good candidate for the clinical trial
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• No chemotherapy or radiotherapy prior to or within 2 weeks of study therapy
• No prior major thoracic and/or abdominal surgery from which the patient has not yet recovered
• No other concurrent investigational drugs
• Concurrent anticancer therapy allowed